How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and more.
External link. We are not responsible for the content.
Read more ↗More From PsyMed Ventures
Mariëlle van Kooten: Virtual Mitochondrial Models and the Case for Engineering Humans
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
The State of Frontier Neuroscience: This is the century of the brain.
Why now, what’s investable & who wins.
Brain Organoids: from Space to AI with Alysson Muotri
Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation...
Latest News
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What f...
The Toads Didn’t Consent to Being Milked, Sorry
Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. [...] Read More... The post T...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the...
Weekly Psychedelic Policy Briefing – August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...